The research, published in the journal ‘The Lancet’, validates temocillin as a safe and effective alternative to carbapenems, last-resort drugs that are losing effectiveness due to increasing bacterial resistance.
The study, named Project Astarté, involved 29 hospitals and analyzed the response of 334 patients. Results were similar between those treated with temocillin and those treated with carbapenems, highlighting the potential of this 'forgotten' drug.
This finding is crucial given the rise in enterobacteria infections, bacteria that can cause severe gastrointestinal illnesses and have developed resistance to conventional treatments.
The research group, part of the CIBERINFEC at the Carlos III Health Institute, aims to reduce carbapenem use and identify new therapeutic options to combat multidrug-resistant bacteria.
